What to expect in the first 72 hours

Most patients' first question before the appointment is a simple one: will it hurt afterwards, and how long will it last? The honest answer is that some discomfort is expected — but it is short-lived and a sign the joint is responding normally, not a sign that something has gone wrong.

The three things most people notice in the first day or two after a ChondroFiller knee injection are swelling, a dull pressure-like ache, and stiffness. Localised swelling typically peaks at around 24 hours and then settles. The aching that comes with it is not sharp or surgical in character — patients commonly describe it as a deep, pressure-like heaviness rather than acute pain. Joint stiffness tends to follow the same curve, easing through the 48–72 hour window without any specific treatment.

All three of these responses are normal physiological reactions to intra-articular scaffold placement. They are not warning signs. They do not indicate a complication. They are not a reason to contact the clinic unless they continue to worsen after 72 hours rather than gradually settle.

On the activity side, light walking is fine from the outset. What the knee needs to avoid during the first 24–48 hours is high-impact loading — running, jumping, and vigorous sport — to give the collagen scaffold time to gel and stabilise within the defect. After that initial window, a graduated return to normal daily movement is appropriate.

Signs that warrant calling the clinic

Two adverse events carry specific warning profiles worth knowing before leaving the clinic: intra-articular infection and allergic reaction to the collagen material.

Infection — what to watch for

Infection is the most serious risk of any intra-articular knee injection, not a complication unique to ChondroFiller. Its absolute rate in this treatment is very low, but the warning pattern is distinct enough to recognise.

The key contrast is direction of travel. Normal post-injection recovery improves — swelling peaks at around 24 hours and gradually settles. An infection signal moves the other way: joint warmth that escalates rather than eases, redness that spreads beyond the injection site, and swelling that is measurably worse at 72 hours than it was at 48. A fever accompanying those joint signs reinforces the concern. If any combination of these appears after the expected 72-hour recovery window — or at any point the knee is clearly deteriorating rather than settling — contact the clinic promptly rather than waiting to see whether it resolves on its own.

Allergic reaction to the collagen carrier

ChondroFiller's scaffold is derived from murine (rat-tail) Type I collagen. Allergic or hypersensitivity reactions to this material are described as extremely uncommon in the clinical evidence. Importantly, known severe collagen hypersensitivity is an absolute contraindication, and screening for it forms part of the clinical assessment before treatment is offered. A patient who has reached the injection appointment has already been assessed against this criterion.

The safety record: what the data actually show

Numbers are useful here, because the accumulated dataset behind ChondroFiller is unusually large for a cartilage-repair device.

Since 2013, more than 19,000 cases have been treated across over 20 European countries. That experience is consolidated in Meidrix Biomedicals GmbH's Clinical Evaluation Report, Version 09, published in April 2025. Across the entire dataset, zero serious adverse device effects (SADEs) have been recorded — where a SADE is defined as an unintended consequence causing organ damage, hospitalisation, or lasting injury. The overall device complaint rate sits at approximately 0.06%, which is among the lowest figures reported in the cartilage-repair field. The most common device-level issue logged is non-gelation: the collagen scaffold failing to polymerise correctly within the defect. This occurs in roughly 0.01% of cases and is classified as a procedural outcome rather than a patient-harm event.

Those figures are reinforced, to a meaningful degree, by independent data. A 2025 prospective study by Matta et al. (PMC12498443) found no significant difference in complication rates between ChondroFiller-treated patients and controls. The same study noted that fibrous tissue formation occurred only in overfilled defects; flush applications were free of it — a technically relevant finding for clinical technique.

One minor finding worth setting in context: occasional mild knee crepitus has been noted in some patients during follow-up, but it carries no serious outcome implications and is not classified as an adverse event.

The provenance of the headline figures matters and should be stated plainly: the dataset is manufacturer-sponsored post-market surveillance, not an independent randomised trial registry. It also reflects carefully selected patients with focal Grade III or IV defects of up to 6 cm². The safety figures do not automatically extend beyond that population. The Matta study provides genuine external corroboration, but a large-scale independent randomised registry has not yet been conducted. What the data support is a well-characterised, consistently low-risk profile in appropriately selected patients — which is a substantively different claim from 'proven safe' in a general sense.

Who is not a candidate for ChondroFiller

ChondroFiller is indicated for focal, isolated Grade III or IV articular cartilage defects of up to 6 cm² — and the safety figures discussed above apply only within that carefully defined patient group. Several circumstances place a patient outside that evidence base.

• Widespread knee osteoarthritis. ChondroFiller targets discrete, localised defects. Patients with advanced, diffuse joint degeneration fall outside the studied indication; the scaffold is not designed to address whole-joint disease.
• Active malignancy. This is a contraindication across the published guidance, regardless of knee-specific factors.
• Bleeding disorders or anticoagulant therapy. Not an automatic disqualifier, but patients in this group require individual clinical assessment before any intra-articular injection is planned.
• Severe hypersensitivity to collagen or murine-derived products. As noted in the earlier section on warning signs, this is screened for before treatment is offered and represents an absolute contraindication.

None of these criteria apply to most patients who are considering ChondroFiller for a focal cartilage problem. Suitability is confirmed through consultation and imaging review — including assessment of defect size, location, and joint alignment — rather than by self-assessment alone. Patients who fall outside the ChondroFiller indication may still have other injection or surgical pathways worth exploring at that same appointment.

How ChondroFiller safety compares to surgical cartilage repair

Choosing between an injectable scaffold pathway and surgical cartilage repair involves weighing different risk profiles as much as different mechanisms — and the numbers are worth setting out plainly.

Microfracture and ACI/MACI remain valid surgical options for appropriate patients, particularly where defect size or patient profile falls outside what an injection pathway can address. But both carry burdens that a ChondroFiller outpatient injection does not: theatre admission, general or regional anaesthesia, wound infection risk, and a rehabilitation arc that typically runs considerably longer than the post-injection guidance described earlier in this article. The reoperation rate associated with ChondroFiller sits at 3–8%, compared with figures of up to 41% for microfracture and up to 37% for ACI or MACI — a substantive difference that reflects the procedural simplicity of an ultrasound-guided injection versus open or arthroscopic surgical repair.

Structural outcomes support the case for the injectable approach in suitable patients. Post-treatment MRI in European studies shows reduction in bone marrow oedema, diminished periarticular effusion, and visible widening of the joint space — objective markers of biocompatibility rather than harm. MOCART scores of 81.6–84.3 indicate that more than 80% of the treated defect has filled and is integrating with surrounding native cartilage. Functionally, IKDC scores improve by approximately 30 points over 12 months — exceeding the 16.7-point threshold considered clinically meaningful — and 70–85% of patients in published series report meaningful symptom relief at three to five years.

These outcomes reflect the scaffold's role in promoting endogenous repair: it supports the body's own regenerative processes by providing a structural matrix, rather than replacing cartilage directly. For patients who meet the focal-defect criteria outlined in the previous section, that mechanism delivers measurable structural and functional gains within a risk profile meaningfully lower than the surgical alternative pathways.

Getting assessed for ChondroFiller in Lincolnshire

For patients in Lincolnshire and the surrounding area, the pathway from initial interest to injection appointment is straightforward. Suitability for ChondroFiller is confirmed through a consultant-led assessment that includes imaging review — most commonly a knee MRI to characterise the size, depth, and location of the cartilage defect. At the Sleaford NG34 Regeneration Hub, onMRI™ AI-driven cartilage segmentation and T2 mapping can provide objective defect characterisation to support that clinical decision.

Consultations and diagnostics are available at both Lincolnshire Knee sites: Sleaford NG34 and Grantham NG31. Importantly, no GP referral is required and there are no NHS-style waiting lists — patients can book directly.

Once suitability is confirmed, the ChondroFiller injection is arranged as an ultrasound-guided outpatient appointment. There is no theatre admission, no general anaesthetic, and no surgical wound to manage.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral. Book an assessment at lincolnshireknee.co.uk.